1. Search Result
Search Result
Results for "

Betulinic acid

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

1

Peptides

8

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10529
    Betulinic acid
    30+ Cited Publications

    Lupatic acid; Betulic acid

    Apoptosis Topoisomerase HIV Autophagy Mitophagy NF-κB Endogenous Metabolite Parasite Infection Neurological Disease Inflammation/Immunology Cancer
    Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties . Betulinic acid can cross the blood-brain barrier .
    Betulinic acid
  • HY-N0084
    Betulinaldehyde
    5 Publications Verification

    Betulinic aldehyde; Betunal

    Bacterial Infection Cardiovascular Disease Cancer
    Betulinaldehyde (Betunal) Has anti-cancer and anti-staphylococcus aureus activity. Betulinaldehyde Suppressible Akt, MAPK sum STAT3 Signal path, increase self-transfer, Suppression A549 Cellular vitality, increase and transfer. Betulinaldehyde suppresses PLCγ1/Ca 2+/MMP9 signal pathway, has a key effect on vascular plasticity, and is available for cardiovascular disease (CVD) research.
    Betulinaldehyde
  • HY-41121
    Boc-L-Ala-OH
    1 Publications Verification

    Boc-Ala-OH

    Amino Acid Derivatives Cancer
    Boc-L-Ala-OH (Boc-Ala-OH) is a single N-protected amino acid ligand and a protected L-alanine derivative. Boc-L-Ala-OH promotes Pd (II)-catalyzed enantioselective C-H alkenylation and kinetic resolution. Boc-L-Ala-OH serves as a coupling reagent for the synthesis of liver-targeted glycogen phosphorylase inhibitors and P6A metabolites, and also acts as a negative control in synthesis studies of betulinic acid amino acid esters. Boc-L-Ala-OH is applicable to research on epidermoid squamous cell carcinoma .
    Boc-L-Ala-OH
  • HY-10529R

    Lupatic acid (Standard); Betulic acid (Standard)

    Reference Standards Apoptosis Topoisomerase HIV Autophagy Mitophagy NF-κB Endogenous Metabolite Parasite Infection Inflammation/Immunology Cancer
    Betulinic acid (Standard) is the analytical standard of Betulinic acid. This product is intended for research and analytical applications. Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties . Betulinic acid can cross the blood-brain barrier.
    Betulinic acid (Standard)
  • HY-N6587

    Methyl betulinate

    Parasite Others
    Betulinic acid methyl ester, a betulinic acid derivative, possesses antiprotozoal activity .
    Betulinic acid methyl ester
  • HY-W744739

    Lupatic acid-d3; Betulic acid-d3

    Isotope-Labeled Compounds Apoptosis Topoisomerase HIV Autophagy Mitophagy NF-κB Endogenous Metabolite Parasite Infection Inflammation/Immunology Cancer
    Betulinic acid-d3 (Lupatic acid-d3) is a deuterium labeled Betulinic acid (HY-10529). Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties . Betulinic acid can cross the blood-brain barrier.
    Betulinic acid-d3
  • HY-N3361

    Others Cancer
    (3β,4α)-Lup-20(29)-ene-3,23-diol (compound 11) is a natural lupane-type triterpenes betulinic acid with anti-tumor activity .
    (3β,4α)-Lup-20(29)-ene-3,23-diol
  • HY-101597

    Apoptosis Cancer
    NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC50=3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP .
    NVX-207
  • HY-N9857

    Others Others
    Betulinic acid palmitate is a natural product .
    Betulinic acid palmitate
  • HY-149547

    Drug Derivative Cancer
    DRF-4015 (Compound 22) is a betulinic acid derivative with antitumor activity .
    DRF-4015
  • HY-155542

    ROR Cancer
    RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells .
    RORγ antagonist 1
  • HY-115720

    Drug Derivative Inflammation/Immunology
    Betulinic acid derivative-1 exhibits distinguished activities on inhibiting osteoclast (OC) differentiation with an IC50 value of 1.86 μM.
    Betulinic acid derivative-1
  • HY-N9477

    Betulin-28-oxime

    Drug Derivative Bacterial Infection
    Betulinic aldehyde oxime (Compound 31) is a betulin (HY-N0083) derivative that has antimicrobial properties against E. aerogenes, E. coli, E. faecalis, P. aeruginosa, S. aureus, and C. albicans. Betulinic aldehyde oxime displays cytotoxicity towards hepatocytes, with an IC50 of 25 μM .
    Betulinic aldehyde oxime
  • HY-146338

    HIV Infection
    RPR103611, the betulinic acid derivative, is a potent HIV-1 entry inhibitor with IC50s of 80, 0.27, and 0.17 for CCR5-tropic virus YU2, CXCR4-tropic virus NL4-3 and dual tropic virus 89.6, respectively .
    RPR103611
  • HY-169479

    Drug Derivative Infection Cancer
    Betulinic glycine amide (compound 5a) is a pentacyclic triterpenoid and derivative of Betulinic acid (HY-10529). Betulinic glycine amide has been used as a precursor in the synthesis of betulinic acid derivatives with anticancer and antiviral activity .
    Betulinic glycine amide
  • HY-186162

    Drug Derivative Others
    Betulinic acid-OBn is a derivative of Betulinic acid (HY-10529) .
    Betulinic acid-OBn
  • HY-186162A

    Drug Isomer Others
    (R)-Betulinic acid-OBn is an isomer of Betulinic acid-OBn(HY-186162) .
    (R)-Betulinic acid-OBn
  • HY-177050

    G protein-coupled Bile Acid Receptor 1 Metabolic Disease Inflammation/Immunology
    RG-239 is an orally active TGR5 agonist with an EC50 of 120 nM, significantly outperforming Betulinic acid (HY-10529) (EC50 = 1.04 μM). RG-239 demonstrates higher selectivity for TGR5 compared to the FXRα. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS (HY-D1056)-induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes [1][2][3][4][5].
    RG-239
  • HY-N18345A

    Drug Derivative Cancer
    Paliurusene A is a betulinic acid-type pentacyclic triterpenoid that can be isolated from the leaves of Paliurus ramosissimus (Lour.) Poir. Paliurusene A induces growth inhibition of human hepatoma cells in vitro. Paliurusene A is applicable to research related to liver cancer .
    Paliurusene A
  • HY-E71272

    Biochemical Assay Reagents Others
    β-Amyrin 28-monooxygenase (EC 1.14.13.201), found in plants, is involved in the biosynthesis of oleanane-type triterpenoids, such as ginsenoside Ro. The enzyme from Medicago trunculata (CYP716A12) can also convert α-amyrin and lupeol to ursolic acid and betulinic acid, respectively.
    β-Amyrin 28-monooxygenase
  • HY-101597R

    Reference Standards Apoptosis Cancer
    NVX-207 (Standard) is the analytical standard of NVX-207 (HY-101597). This product is intended for research and analytical applications. NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC50=3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP .
    NVX-207 (Standard)
  • HY-178355

    Drug Derivative Metabolic Disease
    Anti-osteoporosis agent-12 (Compound 18) is an orally active pyrazole-fused betulinic acid derivative with potent anti-osteoporosis activity. Anti-osteoporosis agent-12 exhibits a strong inhibitory effect on RANKL-induced osteoclastogenesis in RAW264.7 cells, with an IC50 of 7.96 nM. Anti-osteoporosis agent-12 can dose-dependently improve key micro-CT parameters of bone, reduce the level of serum bone resorption marker (CTx), and effectively prevent ovariectomy-induced bone loss. Anti-osteoporosis agent can be used for the study of osteoporosis .
    Anti-osteoporosis agent-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: